The Value of 68Ga-FAPI PET/CT in Preoperative Evaluation of Thyroid Cancer with Lymph Node Metastases

Launched by RUIJIN HOSPITAL · Dec 9, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the use of a special imaging test called 68Ga-FAPI PET/CT to help doctors evaluate thyroid cancer that has spread to nearby lymph nodes before surgery. The goal is to see if this imaging technique can provide valuable information about the cancer, which could improve treatment decisions for patients.

To participate, individuals must be diagnosed with thyroid cancer that has spread to lymph nodes and be between the ages of 16 and 80. They will need to give their consent to join the study and agree to follow the research procedures. However, those with serious health conditions, pregnant or breastfeeding women, and individuals who might not be able to follow the study rules may not be eligible. Participants can expect to undergo the imaging test and will be closely monitored throughout the study. This research aims to enhance understanding and treatment of thyroid cancer, potentially benefiting future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Pathological and clinical diagnosis of thyroid cancer with lymph node metastases.
• • 2. Signed and dated informed consent form.
• • 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process.
• • 4. Aged 16-80 years old.
• Exclusion Criteria:
• • 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
• • 2. Intestinal perforation, complete intestinal obstruction.
• • 3. Pregnant women and women who may be pregnant, women who are breastfeeding.
• • 4. Non-compliant person.